Alizyme plc

Phase IIb trial of cetilistat begins in obese diabetic patients

Published in Aging and Elder Health Week, August 21st, 2005

Alizyme plc (AZM) announces that patient recruitment for the phase IIb clinical trial of cetilistat in obese diabetics has been successfully completed.

The trial is a randomized, double-blind, parallel group design, comparing three doses of cetilistat with placebo and with orlistat (Roche's Xenical). Patients are being treated for 12 weeks with 4 weeks follow up, the primary endpoint being weight loss. In addition, a number of other parameters associated with obesity, including cholesterol and markers for diabetes will be measured. An additional objective of the study is to determine the safety and tolerability profile of cetilistat in these patients, compared to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Aging and Elder Health Week

Source: Aging and Elder Health Week (2005-08-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry